Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Activation in transformed cells of normal stem cells' self-renewal pathways might contribute to the survival life cycle of cancer stem cells and promote tumor progression. The BMI-1 oncogene-driven gene expression pathway is essential for the self-renewal of hematopoietic and neural stem cells. We applied a mouse/human comparative translational genomics approach to identify an 11-gene signature that consistently displays a stem cell-resembling expression profile in distant metastatic lesions as revealed by the analysis of metastases and primary tumors from a transgenic mouse model of prostate cancer and cancer patients. To further validate these results, we examined the prognostic power of the 11-gene signature in several independent therapy-outcome sets of clinical samples obtained from 1,153 cancer patients diagnosed with 11 different types of cancer, including 5 epithelial malignancies (prostate, breast, lung, ovarian, and bladder cancers) and 5 nonepithelial malignancies (lymphoma, mesothelioma, medulloblastoma, glioma, and acute myeloid leukemia). Kaplan-Meier analysis demonstrated that a stem cell-like expression profile of the 11-gene signature in primary tumors is a consistent powerful predictor of a short interval to disease recurrence, distant metastasis, and death after therapy in cancer patients diagnosed with 11 distinct types of cancer. These data suggest the presence of a conserved BMI-1-driven pathway, which is similarly engaged in both normal stem cells and a highly malignant subset of human cancers diagnosed in a wide range of organs and uniformly exhibiting a marked propensity toward metastatic dissemination as well as a high probability of unfavorable therapy outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated expression of this signature is associated with cancer development and chemotherapy resistance in different types of cancer, including hematological malignancies.11”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [11]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536 · cited 4×
“We therefore sought to investigate whether measurements of expression of the 11-gene MTTS/PNS signature would be informative in the prediction of the patients’ prognosis in a group of 97 young women diagnosed with sporadic lymph node– negative early-stage breast cancer who were analyzed in a recent expression profilin…”
BackgroundMethodInfluentialA Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
Bhattacharjee, A., Richards, W. G., Staunton, J., Li, C., Monti, S., Vasa, P., Ladd, C., Beheshti, J., Bueno, R., Gillette, M., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191502998 · Cited by 2,576
Gene expression correlates of clinical prostate cancer behavior
Singh, D., Febbo, P. G., Ross, K., Jackson, D. G., Manola, J., Ladd, C., Tamayo, P., Renshaw, A. A., D'Amico, A. V., Richie, J. P., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00030-2 · Cited by 2,512
Systematic determination of genetic network architecture
Tavazoie, S., Hughes, J. D., Campbell, M. J., Cho, R. J., & Church, G. M. (1999) · Nature Genetics · doi:10.1038/10343 · Cited by 2,507 · cited 1×
“We calculated the significance of the overlap between the lists of stem cell–associated and prostate cancer–associated genes by using the hypergeometric distribution test (54).”
MethodA molecular signature of metastasis in primary solid tumors
Ramaswamy, S., Ross, K. N., Lander, E. S., & Golub, T. R. (2003) · Nature Genetics · doi:10.1038/ng1060 · Cited by 2,449
Shipp, M. A., Ross, K. N., Tamayo, P., Weng, A. P., Kutok, J. L., Aguiar, R. C. T., Gaasenbeek, M., Angelo, M., Reich, M., Pinkus, G. S., et al. (2002) · Nature Medicine · doi:10.1038/nm0102-68 · Cited by 2,428
Cited by
Items 601–700 of 914
Bmi-1 siRNA inhibited ovarian cancer cell line growth and decreased telomerase activity
Xin, T., Zhang, F. B., Sui, G. J., & Jin, X. (2012) · British Journal of Biomedical Science · doi:10.1080/09674845.2012.12002438 · Cited by 15
Phenotypic Screening Reveals Topoisomerase I as a Breast Cancer Stem Cell Therapeutic Target
Zhang, F., Rothermund, K. D., Gangadharan, S. B., Pommier, Y. G., Prochownik, E. V., & Lazo, J. S. (2012) · Oncotarget · doi:10.18632/oncotarget.632 · Cited by 15
“For example, patients with tumors having a higher fraction of breast CSCs would be predicted to have shorter cancer-free intervals, poorer overall survival, and a greater incidence of distant metastasis than individuals with breast tumors containing a low CSC fraction and they do [12, 13].”
Yang, S., He, F., Dai, M., Pan, J., Wang, J., & Ye, B. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s191016 · Cited by 15
“In multiple studies, CHFR gene was found to be significantly silenced by promoter methylation or mutated in a number of cancer types, including gastric cancer,(10) human non-small-cell lung cancer,(11) esophageal cancer,(12) and colorectal cancer.(13) Although increasing evidence supports that CHFR functions as a tumo…”
BackgroundZheng, R., Wang, J., Wu, Q., Wang, Z., Ou, Y., Ma, L., Wang, M., Wang, J., & Yang, Y. F. (2014) · PubMed · Cited by 23
Molecular Biology of Breast Cancer
Aftimos, P. G., Azim, H. A., & Sotiriou, C. P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802761-5.00026-2 · Cited by 16
[Prognostic classification of breast cancer and gene expression profiling].
Bertucci, F., Finetti, P., Cervera, N., & Birnbaum, D. (2008) · Medecine sciences : M/S · doi:10.1051/medsci/20082467599 · Cited by 13
“2005 [37] Cellules souches Affymetrix verre, fluorescence Oligos 12625 11 97”
BackgroundStem cells in head and neck squamous cell carcinoma
Shakib, K., Schrattenholz, A. S., & Šoškić, V. (2010) · British Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.bjoms.2010.07.016 · Cited by 16
Predicting Risk of Breast Cancer Recurrence Using Gene-Expression Profiling
Ignatiadis, M., & Desmedt, C. (2006) · Pharmacogenomics · doi:10.2217/14622416.8.1.101 · Cited by 18
Identification of genes that modulate sensitivity of U373MG glioblastoma cells to cis-platinum
Ma, Y., Yuan, R., Fan, S., Hu, C., Goldberg, I. D., Laterra, J., & Rosen, E. M. (2006) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000217429.67455.18 · Cited by 16
Haura, E. B. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2005.12.050 · Cited by 15
“Finally, a gene expression signature reflecting a normal stem cells’ selfrenewal pattern was identified in primary tumors and tumors with this profile demonstrated a high rate of metastasis and death [19].”
BackgroundGovindan, S. (2015) · Journal of Stem Cell Research & Therapy · doi:10.4172/2157-7633.1000261 · Cited by 14
“The association of a stem cell gene signature with drug resistance and poor prognosis has also been reported in cancers of other sites such as breast and prostate cancers [24,28].”
BackgroundDysregulation of deubiquitination in breast cancer
Kong, L., & Jin, X. (2024) · Gene · doi:10.1016/j.gene.2024.148175 · Cited by 15
Emerson, F. J., Chiu, C., Lin, L. Y., Riedel, C. G., Zhu, M. L., & Lee, S. S. (2024) · Nature Communications · doi:10.1038/s41467-024-46510-6 · Cited by 14
“As all three factors in humans are implicated in neurodevelopment 49,50,56 and cancer 24,51,52 , and HCF-1 ’ s function in cancer has already been linked to the regulation of mitochondrial gene expression 39 , understanding how MLL5, HCF-1, and HDAC1/2 interact and the pathways they regulate in…”
Ubiquitin-specific peptidase 22 controls integrin-dependent cancer cell stemness and metastasis
Liu, K., Gao, Q., Jia, Y., Wei, J., Chaudhuri, S. M., Wang, S., Tang, A., Mani, N. L., Iyer, R., Cheng, Y., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110592 · Cited by 29
Dyrskjøt, L. (2006) · Frontiers in bioscience · doi:10.2741/2211 · Cited by 14
“Recently, general “metastasis signatures” for solid tumors have been developed (54, 55).”
BackgroundLiu, T., Liu, J., Chen, Q., Jin, S., Mi, S., Shao, W., Kudo, Y., Zeng, S., & Qi, G. (2018) · Oncology Letters · doi:10.3892/ol.2018.9837 · Cited by 15
“Our previous research demonstrated that USP22 can positively regulate the expression of Survivin in HCC (7); however, it is unclear whether USP22 regulates the expression of Aurora-B or Survivin in OSCC.”
BackgroundResultInfluentialMelanoma stem cells: targets for successful therapy?
Houben, R., Wischhusen, J., Menaa, F., Synwoldt, P., Schrama, D., Bröcker, E., & Becker, J. C. (2008) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2008.06786.x · Cited by 15
Wang, W., Lin, T., Huang, J., Wei-lie, H., Xu, K., & Liu, J. (2009) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2009.02.004 · Cited by 14
Gene expression determinants of clinical outcome
Buckhaults, P. (2005) · Current Opinion in Oncology · doi:10.1097/01.cco.0000198022.76476.b2 · Cited by 14
Ling, L., Wang, S., Liu, X., Shen, E., Ding, Q., Lu, C., Xu, J., Cao, Q., Zhu, H., & Wang, F. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-4155 · Cited by 14
Essentially all models are wrong, but some are useful
Simard, J. M. (2015) · Neurology · doi:10.1212/wnl.0000000000001769 · Cited by 13
Wang, Y., Gao, Y., Zhou, C., Kong, S., Wang, H., & Yang, J. (2021) · Cells and Development · doi:10.1016/j.cdev.2021.203681 · Cited by 14
Zhang, K., Sun, T., Li, W., Guo, Y., Li, A., Hsieh, M., Wang, J., Wu, J., Arvanitis, L. D., & Raz, D. J. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01320-z · Cited by 16
“USP22 was initially identified as one component of a “Death-By-Cancer ” 11-gene mRNA signature associated with poor prognosis in a variety of cancers [19].”
BackgroundGlinsky, G. V. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.638363 · Cited by 15
“Historically, the theory defining a genomic link between degrees to which a malignancy recapitulates gene expression profiles of stem cells and clinical phenotypes of increased likelihood of therapy failure and death from cancer is originated from the discovery of the death-from-cancer gene expression signature (107).”
BackgroundInfluentialSelf-citationClinical and biologic prognostic factors in malignant pleural mesothelioma
Ambrogi, V., & Mineo, T. C. (2012) · Thoracic Cancer · doi:10.1111/j.1759-7714.2012.00127.x · Cited by 15
Biological features and biomarkers in hepatocellular carcinoma
Chiba, T., Suzuki, E., Saito, T., Ogasawara, S., Ooka, Y., Tawada, A., Iwama, A., & Yokosuka, O. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i16.2020 · Cited by 14
Woodward, W. A., & Hill, R. P. (2016) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-662-49651-0_2 · Cited by 15
“…replenished, if significantly depleted, via dedifferentiation of a previously non-self-renewing cell (Debeb et al. 2012; van Es et al. 2012; Table 1 (continued) Cancer Type Signature Source Prostate, breast, lung, ovarian, bladder, lymphoma, mesothelioma, brain, and leukemia Glinsky et al. (2005).”
BackgroundChung, C. H., Wong, S. J., Ang, K. K., Hammond, E. H., Dicker, A. P., Harari, P. M., & Le, Q. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.04.090 · Cited by 14
Malinowski, D. P. (2007) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.7.3.269 · Cited by 14
Orticello, M., Fiore, M., Totta, P., Desideri, M., Barisic, M., Passeri, D., Lenzi, J., Rosa, A., Orlandi, A., Maiato, H., et al. (2015) · Oncogene · doi:10.1038/onc.2014.265 · Cited by 12
The ubiquitin-specific peptidase 22 is a deubiquitinase of CD73 in breast cancer cells.
Gregory, S., Xu, Y., Xie, P., Fan, J., Gao, B., Mani, N. L., Iyer, R., Tang, A. Y., Wei, J., Chaudhuri, S. M., et al. (2022) · PubMed · Cited by 18
Ubiquitination in osteosarcoma: unveiling the impact on cell biology and therapeutic strategies
Shen, J., Lai, Y., Wu, Y., Lin, X. H., Zhang, C., & Liu, H. (2024) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2024.0231 · Cited by 16
“The identification of Bmi1, Ring1b, and USP22 as “cancer death” markers predicting poor prognosis highlights the potential of histone ubiquitination, but the intricate regulatory mechanisms in cancer remain unclear 116 .”
BackgroundMaugeri‐Saccà, M., D’Andrea, V., Pulcini, A., & Maria, R. D. (2010) · Springer eBooks · doi:10.1007/978-88-470-1658-3_10 · Cited by 12
Drosophila USP22/nonstop polarizes the actin cytoskeleton during collective border cell migration
Badmos, H. A., Cobbe, N., Campbell, A. E., Jackson, R., & Bennett, D. (2021) · The Journal of Cell Biology · doi:10.1083/jcb.202007005 · Cited by 16
Potential biomarkers for radiosensitivity in head and neck cancers
Pardo-Reoyo, S., Roig-Lopez, J. L., & Yang, E. S.-H. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.12.45 · Cited by 12
Zhang, F., Song, X., Li, L., Wang, J., Lin, L., Li, C., Li, H., Lv, Y., Jin, Y., Liu, Y., et al. (2014) · Tumor Biology · doi:10.1007/s13277-014-2920-y · Cited by 12
“It is highly expressed in a variety of human cancers, such as lung [15], leukemia [16], mantle cell lymphoma [17], breast [18], colorectal [19], nasopharyngeal [20], metastatic melanoma [21], oral [22], prostate cancers [23], and ovarian cancer [24].”
BackgroundBmi1 knockdown inhibits hepatocarcinogenesis
Ruan, Z., Xu, R., Lv, Y., Tian, T., Wang, W., Guo, H., & Nan, K. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1693 · Cited by 12
Epigenetic control of cellular senescence in disease: opportunities for therapeutic intervention
Atkinson, S. P., & Keith, W. N. (2007) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399407000269 · Cited by 13
Islam, M. R., Abdulrazak, L. F., Alam, M. K., Paul, B. K., Ahmed, K., Bui, F. M., & Moni, M. A. (2022) · BioMed Research International · doi:10.1155/2022/1776082 · Cited by 11
RetractedGuo, J., Zhao, J., Sun, L., & Chen, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.955718 · Cited by 12
“USP22 is increased during progression from early-stage PC to CRPC, and it has a strong prognostic value in PC (78).”
BackgroundProkakis, E., Bamahmoud, H., Jansari, S., Fritsche, L., Dietz, A., Boshnakovska, A., Rehling, P., Johnsen, S. A., Gallwas, J. K. S., & Wegwitz, F. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01441-5 · Cited by 12
“USP22 was initially identified as a member of a so-called "death-from-cancer" gene expression signature, comprising a group of genes whose expression strongly correlated with cancer aggressiveness, poor response to currently used therapies, tumor relapse and diminished patient survival [13].”
BackgroundZeng, C., Long, J., Deng, C., Xie, L., Ma, H., Guo, Y., Liu, S., & Deng, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.894786 · Cited by 11
“org 9 to be downregulated in several human cancer types, thereby contributing to a poor prognosis (48).”
BackgroundWen, C., Ge, Q., Dai, B., Li, J., Yang, F., Meng, J., Gao, S., Fan, S., & Zhang, L. (2022) · Disease Markers · doi:10.1155/2022/7598942 · Cited by 12
“[27] identified a signature with 11-gene in transgenic mouse models of PCa and cancer patients; this signature always showed a stemcell-like expression profile.”
BackgroundThe Role of Deubiquitinating Enzyme in Head and Neck Squamous Cell Carcinoma
Jin, S., Kudo, Y., & Horiguchi, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010552 · Cited by 14
Akbulut, H., Tang, Y., AKBULUT, K. G., Maynard, J., & Deisseroth, A. B. (2010) · Gene Therapy · doi:10.1038/gt.2010.93 · Cited by 13
Breast Cancer-Initiating Cells: Insights into Novel Treatment Strategies
Santilli, G., Binda, M., Zaffaroni, N., & Daidone, M. G. (2011) · Cancers · doi:10.3390/cancers3011405 · Cited by 12
“epithelial and non-epithelial cancers [6].”
BackgroundOkamoto, T., Yamazaki, H., Hatano, R., Yamada, T., Kaneko, Y., Xu, C., Dang, N. H., Ohnuma, K., & Morimoto, C. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.08.193 · Cited by 11
Huang, K., Wang, Y.-T., Byadgi, O. V., Huang, T.-Y., Tai, M., Shaw, J., & Yang, C.-H. (2022) · Molecules · doi:10.3390/molecules27123950 · Cited by 13
Studies of Osteotropism on Both Sides of the Breast Cancer–Bone Interaction
Moreau, J. E., Anderson, K., Mauney, J. R., Kaplan, D. L., & Rosenblatt, M. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1402.003 · Cited by 12
Glinsky, G. V. (2015) · Oncoscience · doi:10.18632/oncoscience.237 · Cited by 11
“Since these genotype/phenotype relationships between activation of stemness genomic networks and clinically-lethal therapy-resistant phenotypes of human cancers are readily detectable in the early-stage tumors from cancer patients diagnosed with multiple types of malignancies [17-26], it seems likely to expect that em…”
BackgroundSelf-citationTumors arise from the excessive repair of damaged stem cells
Lǐ, J., Yang, D. Y., Yang, D., Chen, Z., Miao, J. Z., Liu, W., Wang, X., Qiu, Z., Jin, M., & Shen, Z. (2017) · Medical Hypotheses · doi:10.1016/j.mehy.2017.03.005 · Cited by 12
Johnston, W., Catton, C., & Swallow, C. J. (2019) · BMC Urology · doi:10.1186/s12894-018-0433-5 · Cited by 10
Use of gene-expression profiling to recommend adjuvant chemotherapy for breast cancer.
Henry, N. L., & Hayes, D. F. (2007) · PubMed · Cited by 9
Xiong, J., Xu, X., Zhou, X., LIU, J., Gong, Z., Wu, P., & Li, W. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2666 · Cited by 10
“In addition, USP22 is overexpressed in numerous human tumors and is associated with treatment resistance, tumor aggressiveness and increased metastasis in cancer patients (6,7).”
BackgroundDou, Y., Lin, J.-P., Shu, H., & Jiang, N. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2589 · Cited by 10
“Overexpression of USP22 was identified in tumors derived from different tissues, as determined by DNA microarray analyses (18).”
Genomic Validation of 3-Tiered Clinical Subclassification of High-Risk Prostate Cancer
Muralidhar, V., Zhang, J., Wang, Q., Mahal, B. A. V., Butler, S. S., Spratt, D. E., Davicioni, E., Sartor, O. A., Feng, F. Y.-C., Mouw, K. W., et al. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.06.2510 · Cited by 11
Expression Biomarkers for Clinical Efficacy and Outcome Prediction in Cancer
Strand, K. J., Khalak, H. G., Strovel, J. W., Ebner, R., & Augustus, M. (2005) · Pharmacogenomics · doi:10.2217/14622416.7.1.105 · Cited by 10
Calvo, A., Perez‐Stable, C., Segura, V., Catena, R., Guruceaga, E., Nguewa, P., Blanco, D., Parada, L. A., Reiner, T., & Green, J. E. (2010) · The Prostate · doi:10.1002/pros.21097 · Cited by 10
“prostate carcinomas have found very heterogeneous results between patients [31–33].”
Lee, J., Kim, M. S., Kim, M. A., & Jang, Y. K. (2016) · Toxicology in Vitro · doi:10.1016/j.tiv.2016.05.015 · Cited by 11
Qin, B., Lu, G., Chen, X., Zheng, C., Lin, H., Liu, Q., Shang, J., & Feng, G. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107345 · Cited by 9
Bai, G., Zheng, W., & Ma, W. (2018) · Oncology Letters · doi:10.3892/ol.2018.8221 · Cited by 10
“NDC80 is overexpressed in a variety of human cancers, such as gastric and breast cancer (51,52), and is associated with multiple cancers (53,54).”
Deubiquitination in prostate cancer progression: role of USP22
Nag, N., & Dutta, S. (2020) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2020.23 · Cited by 10
“The expression of a 11-gene signature in primary prostate tumors was shown to correlate with therapeutic failure in PCa patients[17].”
BackgroundLimitations of Explainability for Established Prognostic Biomarkers of Prostate Cancer
Manjang, K., Yli-Harja, O. P., Dehmer, M., & Emmert‐Streib, F. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.649429 · Cited by 14
Glinsky, G. V., Godugu, K., Sudha, T., Rajabi, M., Chittur, S. V., Hercbergs, A. A., Mousa, S. A., & Davis, P. J. (2022) · Metabolites · doi:10.3390/metabo12040325 · Cited by 8
“The workflow of microarray analyses was reported in previously published contributions [29,30,39,53].”
MethodSelf-citationAn identification of stem cell‐resembling gene expression profiles in high‐grade astrocytomas
Yang, Y., Qiu, Y., Ren, W., Gong, J., & Chen, F. (2008) · Molecular Carcinogenesis · doi:10.1002/mc.20443 · Cited by 9
“Accordingly, a clinical outcome analysis, which utilized the stem cell-resembling transcriptional profile of 11-gene signature, has been shown to predict therapy failure resulted from highly malignant cancer progression in both epithelial and nonepithelial malignancies [46].”
MethodMolecular Mechanisms of Senescence and Implications for the Treatment of Myeloid Malignancies
Ernst, P., & Heidel, F. H. (2021) · Cancers · doi:10.3390/cancers13040612 · Cited by 9
“BMI1 is highly expressed in specific AML subgroups and correlates with therapy failure [105,106].”
BackgroundAmissah, F., Taylor, S., Duverna, R., Ayuk‐Takem, L. T., & Lamango, N. S. (2011) · European Journal of Lipid Science and Technology · doi:10.1002/ejlt.201100030 · Cited by 11
“It (under the pseudonym human carboxylesterase 1) is a member of the 11-gene signature whose expression in primary tumors is a strong indicator of rapid recurrence and poor therapeutic outcomes and death (54).”
BackgroundPellegrini, M. (2023) · Scientific Reports · doi:10.1038/s41598-023-35023-9 · Cited by 7
USP22 Promotes Osteosarcoma Progression by Stabilising β‐Catenin and Upregulating HK2 and Glycolysis
Chen, S., Hu, X., Yi, X., Deng, X., Xiong, T., Ou, Y., Liu, S., Li, C., Yan, X., & Hao, L. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70239 · Cited by 10
“USP22 is among 11 genes that are strongly correlated with tumour invasion, chemotherapy resistance and prognosis [44].”
Maroni, G., Krishnan, I., Alfieri, R. R., Maymi, V. A., Pandell, N., Csizmadia, E., Zhang, J., Weetall, M. L., Branstrom, A., Braccini, G., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0161 · Cited by 10
Bhattacharyya, J., Mihara, K., Kitanaka, A., Yanagihara, K., Kubo, T., Takei, Y., Kimura, A., & Takihara, Y. (2012) · Blood Cancer Journal · doi:10.1038/bcj.2012.21 · Cited by 8
Silencing Bmi-1 expression by RNA interference suppresses the growth of laryngeal carcinoma cells
Yao, X., Wang, X., Liu, H., Zhang, S., & ZHU, H.-L. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1312 · Cited by 8
“In particular, Bmi-1 is overexpressed in a number of malignancies, including mantle cell lymphoma (6), B-cell non-Hodgkin's lymphoma (7), myeloid leukemia (8), non-small cell lung cancer (9), colorectal cancer (10), as well as breast and prostate cancers (11,12).”
Mayburd, A. L., & Baranova, A. V. (2013) · BMC Systems Biology · doi:10.1186/1752-0509-7-121 · Cited by 11
“For example, a reliable cancer mortality signature was produced by meta-analysis for the consensus changes observed in a variety of experiments across a number of model organisms [15].”
BackgroundA Meta-Analysis Approach for Characterizing Pan-Cancer Mechanisms of Drug Sensitivity in Cell Lines
Wang, K., Shrestha, R., Wyatt, A. W., Reddy, A., Lehár, J., Wang, Y., Lapuk, A. V., & Collins, C. C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103050 · Cited by 10
Generation of Human Cell Lines Using Lentiviral-Mediated Genetic Engineering
Salmon, P. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-125-7_25 · Cited by 14
A new transgenic mouse model for conditional overexpression of the Polycomb Group protein EZH2
Koppens, M. A. J., Tanger, E., Nacerddine, K., Westerman, B. A., Song, J., & van Lohuizen, M. (2016) · Transgenic Research · doi:10.1007/s11248-016-9993-x · Cited by 8
Cao, Q., Liu, Q., Li, Q., Zhu, S. L., & Yang, Y. (2018) · Asian Journal of Andrology · doi:10.4103/aja.aja_38_18 · Cited by 8
Guo, J., Xia, B.-R., Deng, S.-H., Yang, C. Q., Pi, Y., Cui, B., & Jin, W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.680100 · Cited by 8
Alterations of Histone Modifications in Cancer
Mercurio, C., Plyte, S. E., & Minucci, S. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-388415-2.00004-4 · Cited by 11
Cancer stem cells in urologic cancers
Gedye, C. A., Davidson, A., Elmes, M. R., Cebon, J. S., Bolton, D. M., & Davis, I. D. (2009) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2009.06.010 · Cited by 11
Cofré, J., Saalfeld, K., & Abdelhay, E. (2019) · The Scientific World JOURNAL · doi:10.1155/2019/4714781 · Cited by 13
“This regulatory loop proposed could be reinforced by other nonclassical-Pc-functions as, for example: (i) EZH2 physically interacts directly with β-catenin, functionally improves the Wnt target gene expression and phenotypically leads to the overexpression of c-Myc and cyclin D1 [54, 55], (ii) BMI1 might also act as a…”
BackgroundThe Role of Stem Cells in Pediatric Central Nervous System Malignancies
Manoranjan, B., Garg, N., Bakhshinyan, D., & Singh, S. K. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-16537-0_4 · Cited by 8
The Idea and Evidence for the Tumor Stemness Switch
Das, B., Tsuchida, R., Baruchel, S., Malkin, D. M., & Yeger, H. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-227-8_35 · Cited by 8
“Others found that Bmi-1 is highly expressed in tumor stem cell fraction of a diverse group of tumors including breast, prostate, and lung tumors [51, 59–61].”
BackgroundSei, Y., Forbes, J., Oguz, C., Schaughency, P., Gutierrez-Cruz, G., Naz, F., Brooks, S. R., Dell’Orso, S., Dagur, P. K., Feng, J., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116500 · Cited by 8
Akahoshi, K., Tanaka, S., Mogushi, K., Shimada, S., Matsumura, S., Akiyama, Y., Aihara, A., Mitsunori, Y., Ban, D., Ochiai, T., et al. (2016) · Journal of Gastroenterology · doi:10.1007/s00535-015-1159-8 · Cited by 7
Kuang, X., McAndrew, M. J., Mustachio, L. M., Chen, Y.-J. C., Atanassov, B. S., Lin, K., Lu, Y., Shen, J., Salinger, A. P., Macatee, T. L., et al. (2021) · Cancers · doi:10.3390/cancers13174276 · Cited by 7
“Overexpression of Usp22 was initially correlated with increased tumor growth, metastatic risk, and death from cancer in transcriptomic studies investigating the role of factors that regulate stemness in prostate cancer [2,3].”
BackgroundSudha, T., Godugu, K., Glinsky, G. V., & Mousa, S. A. (2022) · Biomedicines · doi:10.3390/biomedicines10040795 · Cited by 8
Self-citationRetractedEnzymatic Biosensors for Healthcare Applications
Daurai, B., Ramchiary, S. S., & Gogoi, M. (2023) · Springer eBooks · doi:10.1007/978-981-15-6982-1_1 · Cited by 7
Efroni, S., Meerzaman, D. M., Schaefer, C. F., Greenblum, S. I., Soo‐Lyu, M., Hu, Y., Cultraro, C. M., Meshorer, E., & Buetow, K. H. (2013) · IET Systems Biology · doi:10.1049/iet-syb.2010.0078 · Cited by 7
RNA-guided diagnostics and therapeutics for next-generation individualized nanomedicine
Glinsky, G. V. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69268 · Cited by 7
“…highly anticipated technological breakthrough will be essential for critical testing of the validity of the cancer stem cell hypothesis and experimental and clinical assessment of the utility of selective therapeutic targeting of human tumor stemness pathways to prevent clinical progression (28).”
Self-citationBellodi‐Privato, M., Kubrusly, M. S., Stefano, J. T., Soares, I. C., Wakamatsu, A., de Oliveira, A. C. S., Alves, V. A. F., Bacchella, T., Machado, M. C. C., & D′Albuquerque, L. A. C. (2009) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2009005000037 · Cited by 7
“br Braz J Med Biol Res Online Ahead of Print by microarray offers a systematic approach to gaining comprehensive information regarding transcription profiles (9).”
BackgroundFaveri, L. E. D., Hurst, C. D., Roulson, J., Wood, H. M., Sänchez‐Carbayo, M., Knowles, M. A., & Chapman, E. (2015) · Translational Oncology · doi:10.1016/j.tranon.2015.08.002 · Cited by 7
“An 11-gene BMI1 pathway gene signature has been identified in metastatic prostate cancer and neural stem cells and is predictive of poor outcome in multiple tumor types including bladder [55].”
BackgroundBiosensors for Neurological Disease
Bell, K. M., & Kornguth, S. E. (2007) · Wiley eBooks · doi:10.1002/9780470061565.hbb139 · Cited by 7
Cancer stem cells: Opportunities for novel diagnostics and drug discovery
Keith, W. N. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.02.003 · Cited by 7
Wang, X., Su, Y., Lan, B., Li, X., Zhang, B., Zhang, L., Wang, Y., Zhang, C., & Xuan, C. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70324 · Cited by 10
“14 As a member of an 11-gene ‘death-from-cancer’ signature, 15 USP22’s non-WANG histone substrates play a critical role in mediating its pro-oncogenic function.”
Kawata, K., Chapman, O. S., Narumi, S., & Kawauchi, D. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1569548 · Cited by 8
Stem Cells in the Normal and Malignant Prostate
Maitland, N. J. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6828-8_1 · Cited by 9
den Broeck, T. V., Moris, L., Gevaert, T., Davicioni, E., Boeckx, B., Lambrechts, D., Helsen, C., Handle, F., Ghesquière, B., Soenen, S., et al. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0388 · Cited by 6
Methods in Mathematical Modeling for Stem Cells
Eby, W. M., & Tabatabai, M. (2013) · Stem cells and cancer stem cells · doi:10.1007/978-94-017-8032-2_18 · Cited by 7
Cancer Stem Cells and Chemoresistance
Chuthapisith, S. (2011) · InTech eBooks · doi:10.5772/13789 · Cited by 6
“As a result, CSCs are believed to be involved in carcinogenesis, as well as in local invasion and in the metastatic process [Glinsky et al., 2005; Spillane and Henderson, 2007].”
Metadata
- Authors
- Glinsky, G. V., Berezovska, O., & Glinskii, A. B.
- Affiliations
- Sidney Kimmel Cancer Center (US)
- Corresponding author
- Glinsky, Gennadi V.
- ORCID
- Glinsky, Gennadi V.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-06-01
- Volume
- 115
- Issue
- 6
- Pages
- 1503-1521
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1136989
- OpenAlex
- W2166666333
- Cited by
- 916
- References
- 68
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 22 · 2023: 30 · 2022: 25 · 2021: 29 · 2020: 25 · 2019: 27 · 2018: 38 · 2017: 35 · 2016: 30 · 2015: 50 · 2014: 57 · 2013: 51 · 2012: 60
- FWCI
- 34.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Memorial Sloan-Kettering Cancer Center
- National Institutes of Health
- National Cancer Institute (5R01CA89827, R01CA089827)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Keywords
- cancer stem cells, BMI1, stem cell self-renewal, gene expression signatures, metastasis, treatment failure, prognosis, distant metastasis, recurrence, epithelial malignancies, hematologic malignancies, multi-cancer analysis
- MeSH terms
- Animals, Female, Humans, Male, Mice, Transgenic, Neoplasm Metastasis, Neoplasm Recurrence, Local, Neoplasms, Nuclear Proteins, Prognosis, Proto-Oncogene Proteins, Repressor Proteins, Biomarkers, Tumor, Neoplastic Stem Cells, Gene Expression Regulation, Neoplastic, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Mice, Polycomb Repressive Complex 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.